Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Alterations of monetary reward and punishment processing in chronic cannabis users: an FMRI study.

Enzi B, Lissek S, Edel MA, Tegenthoff M, Nicolas V, Scherbaum N, Juckel G, Roser P.

PLoS One. 2015 Mar 23;10(3):e0119150. doi: 10.1371/journal.pone.0119150. eCollection 2015.

2.

['How Much Sex do Medical Studies Need?' - A Survey of the Knowledge and Interest in Sexual Medicine of Medical Students.]

Turner D, Driemeyer W, Nieder TO, Scherbaum N, Briken P.

Psychother Psychosom Med Psychol. 2014 Dec;64(12):452-457. Epub 2014 Dec 10. German.

PMID:
25494185
3.

Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment.

Specka M, Heilmann M, Lieb B, Scherbaum N.

Clin Neuropharmacol. 2014 Nov-Dec;37(6):161-5. doi: 10.1097/WNF.0000000000000050.

PMID:
25384073
4.

[New psychotropic drugs - "legal highs"].

Scherbaum N, Schifano F, Siemann H.

Fortschr Neurol Psychiatr. 2014 Sep;82(9):532-43; quiz 543-4. doi: 10.1055/s-0034-1384916. Epub 2014 Sep 1. German. No abstract available.

PMID:
25177905
5.

Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.

Bonnet U, Specka M, Stratmann U, Ochwadt R, Scherbaum N.

Drug Alcohol Depend. 2014 Oct 1;143:189-97. doi: 10.1016/j.drugalcdep.2014.07.027. Epub 2014 Aug 1.

PMID:
25127704
6.

XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide gene-set-based analysis and follow-up studies in Drosophila and humans.

Juraeva D, Treutlein J, Scholz H, Frank J, Degenhardt F, Cichon S, Ridinger M, Mattheisen M, Witt SH, Lang M, Sommer WH, Hoffmann P, Herms S, Wodarz N, Soyka M, Zill P, Maier W, Jünger E, Gaebel W, Dahmen N, Scherbaum N, Schmäl C, Steffens M, Lucae S, Ising M, Smolka MN, Zimmermann US, Müller-Myhsok B, Nöthen MM, Mann K, Kiefer F, Spanagel R, Brors B, Rietschel M.

Neuropsychopharmacology. 2015 Jan;40(2):361-71. doi: 10.1038/npp.2014.178. Epub 2014 Jul 18.

PMID:
25035082
7.

Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling.

Sowa JP, Atmaca Ö, Kahraman A, Schlattjan M, Lindner M, Sydor S, Scherbaum N, Lackner K, Gerken G, Heider D, Arteel GE, Erim Y, Canbay A.

PLoS One. 2014 Jul 2;9(7):e101444. doi: 10.1371/journal.pone.0101444. eCollection 2014.

8.

KIR2DL3⁺NKG2A⁻ natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs.

Thoens C, Berger C, Trippler M, Siemann H, Lutterbeck M, Broering R, Schlaak J, Heinemann FM, Heinold A, Nattermann J, Scherbaum N, Alter G, Timm J.

J Hepatol. 2014 Sep;61(3):475-81. doi: 10.1016/j.jhep.2014.04.020. Epub 2014 Apr 26.

PMID:
24780303
9.

Can reinforcement-based interventions to reduce drug use successfully be adapted to routine opioid maintenance treatment?

Specka M, Böning A, Kluwig J, Schifano F, Banger M, Lange W, Lax H, Marrziniak B, Schüngel C, Scherbaum N.

Ann Ist Super Sanita. 2013;49(4):358-64. doi: DOI: 10.4415/ANN_13_04_07.

10.

[Outcomes of comprehensive inpatient opiate detoxification in patients re-admitted to treatment within one year].

Specka M, Lopez Gonzales K, Scherbaum N.

Psychiatr Prax. 2015 Jan;42(1):30-4. doi: 10.1055/s-0033-1349558. Epub 2013 Nov 19. German.

PMID:
24254425
11.

Attenuated Readiness Potential in the Absence of Executive Dysfunction in Adults With ADHD.

Seo BK, Sartory G, Kis B, Scherbaum N, Müller BW.

J Atten Disord. 2013 Oct 25. [Epub ahead of print]

PMID:
24163327
12.

Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial.

Reimer J, Schmidt CS, Schulte B, Gansefort D, Gölz J, Gerken G, Scherbaum N, Verthein U, Backmund M.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S97-104. doi: 10.1093/cid/cit307.

13.

Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.

Corazza O, Assi S, Simonato P, Corkery J, Bersani FS, Demetrovics Z, Stair J, Fergus S, Pezzolesi C, Pasinetti M, Deluca P, Drummond C, Davey Z, Blaszko U, Moskalewicz J, Mervo B, Furia LD, Farre M, Flesland L, Pisarska A, Shapiro H, Siemann H, Skutle A, Sferrazza E, Torrens M, Sambola F, van der Kreeft P, Scherbaum N, Schifano F.

Hum Psychopharmacol. 2013 Jul;28(4):317-23. doi: 10.1002/hup.2299.

PMID:
23881879
14.

Topical review on the abuse and misuse potential of tramadol and tilidine in Germany.

Radbruch L, Glaeske G, Grond S, Münchberg F, Scherbaum N, Storz E, Tholen K, Zagermann-Muncke P, Zieglgänsberger W, Hoffmann-Menzel H, Greve H, Cremer-Schaeffer P.

Subst Abus. 2013;34(3):313-20. doi: 10.1080/08897077.2012.735216. Review.

PMID:
23844964
15.

[Opiate dependency].

Scherbaum N, Lieb B.

Fortschr Neurol Psychiatr. 2013 Jun;81(6):346-57; quiz 358. doi: 10.1055/s-0033-1335646. Epub 2013 Jun 17. Review. German. No abstract available.

PMID:
23775167
16.

αCaMKII autophosphorylation controls the establishment of alcohol drinking behavior.

Easton AC, Lucchesi W, Lourdusamy A, Lenz B, Solati J, Golub Y, Lewczuk P, Fernandes C, Desrivieres S, Dawirs RR, Moll GH, Kornhuber J, Frank J, Hoffmann P, Soyka M, Kiefer F; GESGA Consortium, Schumann G, Peter Giese K, Müller CP, Treutlein J, Cichon S, Ridinger M, Mattheisen P, Herms S, Wodarz N, Zill P, Maier W, Mössner R, Gaebel W, Dahmen N, Scherbaum N, Schmäl C, Steffens M, Lucae S, Ising M, Müller-Myhsok B, Nöthen MM, Mann K, Rietschel M.

Neuropsychopharmacology. 2013 Aug;38(9):1636-47. doi: 10.1038/npp.2013.60. Epub 2013 Mar 4. Erratum in: Neuropsychopharmacology. 2013 Dec;38(13):2735.

17.

Craving in alcohol-dependent patients after detoxification is related to glutamatergic dysfunction in the nucleus accumbens and the anterior cingulate cortex.

Bauer J, Pedersen A, Scherbaum N, Bening J, Patschke J, Kugel H, Heindel W, Arolt V, Ohrmann P.

Neuropsychopharmacology. 2013 Jul;38(8):1401-8. doi: 10.1038/npp.2013.45. Epub 2013 Feb 12.

18.

Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.

Apelt SM, Scherbaum N, Gölz J, Backmund M, Soyka M.

Pharmacopsychiatry. 2013 May;46(3):94-107. doi: 10.1055/s-0032-1330033. Epub 2013 Jan 4.

PMID:
23293011
19.

Structural brain alterations associated with schizophrenia preceded by conduct disorder: a common and distinct subtype of schizophrenia?

Schiffer B, Leygraf N, Müller BW, Scherbaum N, Forsting M, Wiltfang J, Gizewski ER, Hodgins S.

Schizophr Bull. 2013 Sep;39(5):1115-28. doi: 10.1093/schbul/sbs115. Epub 2012 Sep 26.

20.

Craving dominates propofol addiction of an affected physician.

Bonnet U, Scherbaum N.

J Psychoactive Drugs. 2012 Apr-Jun;44(2):186-90.

PMID:
22880547
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk